Panobinostat sensitizes KRAS-mutant non-small-cell lung cancer to gefitinib by targeting TAZ

Transcriptional Selectivity of Epigenetic Therapy in Cancer

(2016) Takahiro Sato et al.   CANCER RESEARCH

The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects

(2016) J. Shahbazi et al.   CLINICAL CANCER RESEARCH

The pan-HDAC inhibitor panobinostat acts as a sensitizer for erlotinib activity in EGFR-mutated and -wildtype non-small cell lung cancer cells

(2015) Gabriele Greve et al.   BMC CANCER

DUSP1 Expression Induced by HDAC1 Inhibition Mediates Gefitinib Sensitivity in Non-Small Cell Lung Cancers

(2015) Y.-C. Lin et al.   CLINICAL CANCER RESEARCH

Panobinostat for the Treatment of Multiple Myeloma

(2015) J. P. Laubach et al.   CLINICAL CANCER RESEARCH

Functionally defined therapeutic targets in diffuse intrinsic pontine glioma

(2015) Catherine S Grasso et al.   NATURE MEDICINE

The predictive value of ERCC1 and p53 for the effect of panobinostat and cisplatin combination treatment in NSCLC

(2015) Yang Cai et al.   Oncotarget

Combining BET and HDAC inhibitors synergistically induces apoptosis of melanoma and suppresses AKT and YAP signaling

(2015) Anja Heinemann et al.   Oncotarget

Up-regulation of the Hippo pathway effector TAZ renders lung adenocarcinoma cells harboring EGFR-T790M mutation resistant to gefitinib

(2015) Wei Xu et al.   Cell and Bioscience

Yap1 Activation Enables Bypass of Oncogenic Kras Addiction in Pancreatic Cancer

(2014) Avnish Kapoor et al.   CELL

A Phase I, Pharmacokinetic, and Pharmacodynamic Study of Panobinostat, an HDAC Inhibitor, Combined with Erlotinib in Patients with Advanced Aerodigestive Tract Tumors

(2014) J. E. Gray et al.   CLINICAL CANCER RESEARCH

PI3K/mTOR Inhibition Markedly Potentiates HDAC Inhibitor Activity in NHL Cells through BIM- and MCL-1-Dependent Mechanisms In Vitro and In Vivo

(2014) M. Rahmani et al.   CLINICAL CANCER RESEARCH

An Integrative Analysis of the Tumorigenic Role of TAZ in Human Non-Small Cell Lung Cancer

(2014) S. Noguchi et al.   CLINICAL CANCER RESEARCH

Tumor-propagating cells and Yap/Taz activity contribute to lung tumor progression and metastasis

(2014) A. N. Lau et al.   EMBO JOURNAL

The combination of irreversible EGFR TKIs and SAHA induces apoptosis and autophagy-mediated cell death to overcome acquired resistance in EGFRT790M-mutated lung cancer

(2014) Tae-Gul Lee et al.   INTERNATIONAL JOURNAL OF CANCER

TAZ is required for metastatic activity and chemoresistance of breast cancer stem cells

(2014) M Bartucci et al.   ONCOGENE

Downstream of Mutant KRAS, the Transcription Regulator YAP Is Essential for Neoplastic Progression to Pancreatic Ductal Adenocarcinoma

(2014) W. Zhang et al.   Science Signaling

The PI3K/AKT pathway promotes gefitinib resistance in mutantKRASlung adenocarcinoma by a deacetylase-dependent mechanism

(2013) Victor Jeannot et al.   INTERNATIONAL JOURNAL OF CANCER

LBH589 Inhibits proliferation and metastasis of hepatocellular carcinoma via inhibition of gankyrin/stat3/akt pathway

(2013) Xuan Song et al.   Molecular Cancer

Regulation of Hippo pathway by mitogenic growth factors via phosphoinositide 3-kinase and phosphoinositide-dependent kinase-1

(2013) R. Fan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

TAZ induces growth factor-independent proliferation through activation of EGFR ligand amphiregulin

(2012) Nuo Yang et al.   CELL CYCLE

Biomarker Discovery in Non-Small Cell Lung Cancer: Integrating Gene Expression Profiling, Meta-analysis, and Tissue Microarray Validation

(2012) J. Botling et al.   CLINICAL CANCER RESEARCH

Identification of Genes Upregulated in ALK-Positive and EGFR/KRAS/ALK-Negative Lung Adenocarcinomas

(2011) H. Okayama et al.   CANCER RESEARCH

The Hippo Transducer TAZ Confers Cancer Stem Cell-Related Traits on Breast Cancer Cells

(2011) Michelangelo Cordenonsi et al.   CELL

Cytotoxic activity of the histone deacetylase inhibitor panobinostat (LBH589) in anaplastic thyroid cancer in vitro and in vivo

(2011) Maria Graziella Catalano et al.   INTERNATIONAL JOURNAL OF CANCER

EGFR and MET receptor tyrosine kinase–altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers

(2011) Michela Garofalo et al.   NATURE MEDICINE

TAZ is a novel oncogene in non-small cell lung cancer

(2011) Z Zhou et al.   ONCOGENE

Phosphoinositide 3-Kinase/Akt Inhibits MST1-Mediated Pro-apoptotic Signaling through Phosphorylation of Threonine 120

(2009) Zengqiang Yuan et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Clinical outcome of patients with non-small cell lung cancer receiving front-line chemotherapy according to EGFR and K-RAS mutation status

(2009) Aristea Kalikaki et al.   LUNG CANCER

The HDAC inhibitor panobinostat (LBH589) inhibits mesothelioma and lung cancer cells in vitro and in vivo with particular efficacy for small cell lung cancer

(2009) M. C. Crisanti et al.   MOLECULAR CANCER THERAPEUTICS

Prediction of Recurrence-Free Survival in Postoperative Non-Small Cell Lung Cancer Patients by Using an Integrated Model of Clinical Information and Gene Expression

(2008) E.-S. Lee et al.   CLINICAL CANCER RESEARCH

Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer

(2008) Helena Linardou et al.   LANCET ONCOLOGY